Business
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFT...
About this update from Vortex Energy Corp.
[{"type":"text","content":"\n\n\n\n Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV\n \n\n\n 1\n \n and superior in reducing sweat chloride compared to\n \n\n TRIKAFTA -\n \n\n\n\n -\n \n\n Approximately 3,800 people in\n \n Canada\n \n are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time -\n \n\n\n\n\n TORONTO\n \n\n ,\n \n\n July 22, 2025\n \n\n /CNW/ -\n \n Vertex Pharmaceuticals\n \n today announced that Health Canada has granted Marketing Authorization for\n \n Pr\n \n ALYFTREK\n \n TM\n \n (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one\n \n F508del\n \n mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (\n \n CFTR\n \n ) gene.\n \n\n\n\n\n\n\n\n\n ALYFTREK brings a potentially transformative therapy to up to 60 people living with CF in\n \n Canada\n \n who were not previously eligible for a CFTR modulator. As the first once-daily CFTR modulator, ALYFTREK may also provide a new treatment option and flexibility for approximately 3,800 people given the need to take CFTR modulators with fat-containing food.\n \n\n \"ALYFTREK represents the next generation of CFTR modulator treatment and is a testament to our long-standing goal to address the underlying cause of cystic fibrosis, treat more people living with CF, and bring more people to normal levels of CFTR function,\" said\n \n Michael Siauw\n \n , General Manager at Vertex Pharmaceuticals (\n \n Canada\n \n ) Incorporated. \"With once-daily dosing, eligibility in 113 additional mutations, and the potential to lower sweat chloride levels even further, ALYFTREK brings us one step closer to ac...